No profile data available.
Aquestive Therapeutics, Inc. (AQST) is a healthcare company in the poison treatment pharmaceuticals industry, based in Warren, United States, with about 147 full-time employees.
It reported revenue of $44.55 million for fiscal year 2025, down 22.6% from fiscal year 2024, and net income of -$83.78 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $13.82 million, up 38.1% from a year before. United States was its largest region in fiscal year 2025, with 66% of revenue. Its market capitalization was $599.95 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Aquestive Therapeutics reported $44.55 million in revenue for fiscal year 2025, down 22.6% from $57.56 million in fiscal year 2024. In Q2 2026 revenue was $13.82 million.
United States: 66% of revenue by region in fiscal year 2025, followed by Ex-United States (34%).
$599.95 million as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Indivior PLC (INDV), Achieve Life Sciences, Inc. (ACHV), Fennec Pharmaceuticals Inc. (FENC), Anebulo Pharmaceuticals, Inc. (ANEB).